

**Supplementary Table 6.** Low-Density Lipoprotein: Number of Patients With Different Average Postbaseline Status During AE Period (Safety Population)

<b>LDL baseline*</b> <b>Postbaseline n/N1, (%)</b>	<b>Adalimumab 40 mg q2w (n=184)</b>	<b>Sarilumab 200 mg q2w (n=184)</b>
<100 mg/dL		
<100 mg/dL	52/63 (82.5)	36/63 (57.1)
100 to <130 mg/dL	10/63 (15.9)	24/63 (38.1)
130 to <160 mg/dL	0/63	3/63 (4.8)
160 to <190 mg/dL	1/63 (1.6)	0/63
≥190 mg/dL	0/63	0/63
100 to <130 mg/dL		
<100 mg/dL	15/57 (26.3)	10/68 (14.7)
100 to <130 mg/dL	37/57 (64.9)	28/68 (41.2)
130 to <160 mg/dL	5/57 (8.8)	23/68 (33.8)
160 to <190 mg/dL	0/57	7/68 (10.3)
≥190 mg/dL	0/57	0/68
130 to <160 mg/dL		
<100 mg/dL	1/41 (2.4)	1/33 (3.0)
100 to <130 mg/dL	13/41 (31.7)	4/33 (12.1)
130 to <160 mg/dL	22/41 (53.7)	17/33 (51.5)
160 to <190 mg/dL	5/41 (12.2)	10/33 (30.3)
≥190 mg/dL	0/41	1/33 (3.0)
160 to <190 mg/dL		
<100 mg/dL	0/11	1/15 (6.7)
100 to <130 mg/dL	2/11 (18.2)	0/15
130 to <160 mg/dL	4/11 (36.4)	6/15 (40.0)
160 to <190 mg/dL	3/11 (27.3)	3/15 (20.0)
≥190 mg/dL	2/11 (18.2)	5/15 (33.3)
≥190 mg/dL		
<100 mg/dL	0/8	0/4
100 to <130 mg/dL	0/8	0/4
130 to <160 mg/dL	1/8 (12.5)	2/4 (50.0)
160 to <190 mg/dL	3/8 (37.5)	0/4
≥190 mg/dL	4/8 (50.0)	2/4 (50.0)

---

\*The number (n) represents the subset of the total number of patients who met the criterion in question at least once during treatment. The denominator (/N1) for each parameter within a treatment group is the number of patients for the treatment group who had that parameter assessed postbaseline. The average of all postbaseline measurements for each patient is presented by baseline status.

AE, adverse event; LDL, low-density lipoprotein; q2w, every 2 weeks.